drugset / Trial / NCT02873962
A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib
Phase 2
Active not recruiting
72 enrolled
Dana-Farber Cancer Institute
Bristol-Myers Squibb · collabClovis Oncology, Inc. · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
This research study is evaluating three drugs called Nivolumab, Bevacizumab, and Rucaparib as a possible treatment for relapsed Relapsed Ovarian, Fallopian Tube Or Peritoneal Cancer.
Timeline
- Start
- 2016-11-10
- Primary completion
- 2025-02
- Completion
- 2027-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | — | Intravenous |
| Subject | Nivolumab | Monoclonal antibody | — | Intravenous |
| Subject | Rucaparib | Small molecule | — | Oral |